Hims & Hers Health (NYSE:HIMS) Stock: Insider Soleil Boughton Sells 3,462 Shares

October 30, 2026 by InsiderTrades.com

Key Points

Insider Soleil Boughton sold 3,462 Hims & Hers shares for approximately $95,551 at an average price of $27.60 under a pre-arranged Rule 10b5-1 plan, reducing the position by 1.16% to 293,886 shares.
Hims & Hers reported quarterly revenue of $753.2 million, up 38.2% year over year and above estimates, but its loss of $0.37 per share significantly missed expectations. The company maintains negative net margins and analysts expect a consensus “Hold” rating with an average price target of $32.43.
The company faces ongoing legal and regulatory uncertainty, including a securities class-action deadline tied to allegations involving customer data sharing and billing practices, while temporary permission to compound certain peptides could support growth.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 3,462 shares of the stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $27.60, for a total transaction of $95,551.20. Following the transaction, the insider owned 293,886 shares in the company, valued at approximately $8,111,253.60. The trade was a 1.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks

Soleil Boughton also recently made the following trade(s):

On Wednesday, October 14th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.06, for a total transaction of $100,576.66.
On Wednesday, September 30th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.17, for a total transaction of $100,957.37.
On Wednesday, September 16th, Soleil Boughton sold 6,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.86, for a total transaction of $173,734.96.
On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.33, for a total value of $97,965.14.
On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.55, for a total value of $691,808.05.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $29.68 on Friday. The stock's fifty day moving average price is $29.12 and its two-hundred day moving average price is $27.10. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $48.34. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The firm has a market cap of $6.92 billion, a PE ratio of -47.11 and a beta of 2.44.

Is the Market Right or Wrong About These 4 High Short Interest Stocks?

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The company had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. Hims & Hers Health's revenue was up 38.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.17 earnings per share. As a group, research analysts expect that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: The Department of Health and Human Services reportedly used “enforcement discretion” to temporarily permit compounding of six peptides. The decision could expand Hims & Hers’ access to compounded treatments and support its growth prospects, although the authorization is temporary and policy-related uncertainty remains. Hims & Hers Jumped as HHS Uses Enforcement Discretion to Open Peptide Compounding
Positive Sentiment: Hims & Hers also benefited from strength across the telehealth sector after Teladoc reported better-than-expected revenue and profit, improving sentiment toward digital-health companies. Teladoc Soars as Revenue and Profit Beat Estimates
Neutral Sentiment: Insider Soleil Boughton sold 3,462 shares for approximately $95,551 under a pre-arranged Rule 10b5-1 trading plan. The sale reduced the insider’s holdings by about 1.16%, but the planned nature and relatively small size make it a limited signal about management’s outlook. SEC Insider Trading Filing
Negative Sentiment: Multiple law firms reminded investors of a November 2 deadline to seek lead-plaintiff status in a securities class action covering purchases from August 4, 2025, through July 29, 2026. The litigation alleges that Hims & Hers shared customer information with advertising platforms and used deceptive billing practices, claims that could create legal costs, reputational damage and additional regulatory risk. The notices reference allegations connected to the Federal Trade Commission’s complaint; they do not represent a court finding of wrongdoing. HIMS Securities Class Action Deadline Notice

Institutional Investors Weigh In On Hims & Hers Health

MarketBeat Week in Review – 08/24 - 08/28

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. B. Metzler seel. Sohn & Co. AG bought a new position in shares of Hims & Hers Health in the 2nd quarter valued at $2,992,000. FirstWave Capital Management LLC raised its holdings in shares of Hims & Hers Health by 30.6% during the 2nd quarter. FirstWave Capital Management LLC now owns 339,978 shares of the company's stock worth $11,787,000 after buying an additional 79,731 shares in the last quarter. Concurrent Investment Advisors LLC raised its holdings in shares of Hims & Hers Health by 109.8% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 35,272 shares of the company's stock worth $1,223,000 after buying an additional 18,459 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Hims & Hers Health by 126.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 71,646 shares of the company's stock worth $1,487,000 after buying an additional 40,023 shares in the last quarter. Finally, Louisiana State Employees Retirement System bought a new stake in shares of Hims & Hers Health during the 1st quarter worth $1,254,000. 63.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of recent analyst reports. Needham & Company LLC raised their price target on Hims & Hers Health from $35.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Zacks Research raised shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research report on Monday, July 13th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a "hold" rating in a research note on Tuesday, August 11th. Barclays decreased their target price on shares of Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating on the stock in a report on Friday, August 21st. Finally, Citigroup dropped their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set a "neutral" rating for the company in a research report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Hims & Hers Health currently has a consensus rating of "Hold" and an average target price of $32.43.

View Our Latest Report on Hims & Hers Health

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.